Belviq (lorcaserin) side effects: Upper respiratory infection 13.7% of patients, 12.3% with placebo

Posted by .(JavaScript must be enabled to view this email address)
Saturday, June 22, 2013 2:30 pm Email this article

Upper respiratory tract infection was reported in 13.7% of patients given the weight loss drug, Belviq (lorcaserin), versus 12.3% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.

Reference

Belviq (lorcaserin hydrochloride) Prescribing Information. Revision 08/2012.
http://www.belviq.com/pdf/Belviq_Prescribing_information.pdf

 

Articles on the same subject can be found here:

• Belviq (lorcaserin hydrochloride)